Abstract A105: Wild-type IDH1 inhibition enhances chemotherapy response in pancreatic cancer

Mehrdad Zarei,Omid Hajihassani,Jonathan J. Hue,Hallie J. Graor,Alexander W. Loftus,Luke D. Rothermel,Jordan M. Winter
DOI: https://doi.org/10.1158/1538-7445.panca2023-a105
IF: 11.2
2024-01-18
Cancer Research
Abstract:Background and Aims: Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive forms of cancer, with a five-year overall survival rate of 12% among all-comers. Current systemic therapeutic options are limited to cytotoxic chemotherapies which have limited clinical efficacy and are often associated with the rapid development of drug resistance. We examined mechanistic and therapeutic implications of combining anti-wild-type IDH1 therapy with conventional chemotherapeutics to treat PDAC. Methods: Therapeutic responses were tested in vivo and in vitro through survival studies, testing for the effects of ivosidenib (an allosteric IDH1 inhibitor) and PDAC chemotherapeutics. Usage of ivosidenib is based on pre-clinical work showing anti-wild-type IDH1 activity under tumor associated conditions. Results: Chemotherapy treatment of PDAC cells induced the production of reactive oxygen species and increased TCA cycle activity. Treatment also resulted in the rapid induction of wild-type IDH1 expression, which served as a key resistance factor. The enzyme is protective under chemotherapy-associated stress by supporting antioxidant defense and mitochondrial function, through the generation of NADPH and alpha-ketoglutarate, respectively. Pharmacologic suppression of wild-type IDH1 was synergistic with conventional chemotherapeutics in vitro, and potentiated sub-therapeutic doses of these drugs in murine PDAC models. Conclusions: Pharmacologic wild-type IDH1 inhibition with ivosidenib proved to be cooperative with conventional PDAC chemotherapeutics in diverse models. This promising new treatment approach is easily translatable, and provides the basis of an ongoing clinical trial (NCT05209074). Citation Format: Mehrdad Zarei, Omid Hajihassani, Jonathan J. Hue, Hallie J. Graor, Alexander W. Loftus, Luke D. Rothermel, Jordan M. Winter. Wild-type IDH1 inhibition enhances chemotherapy response in pancreatic cancer [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Pancreatic Cancer; 2023 Sep 27-30; Boston, Massachusetts. Philadelphia (PA): AACR; Cancer Res 2024;84(2 Suppl) nr A105.
oncology
What problem does this paper attempt to address?